Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ALNY is in the long-term down -38% below S&P in 2 years.
Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company?s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-4.83||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||154.11%||Sales Growth - Q/Q||-22.82%||P/E||-15.75|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-9.84%||ROE||-10.71%||ROI|
|Current Ratio||13.51||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||-309.32%||Net Profit Margin||-263.44%||Dividend Payout Ratio|
|Cash From Financing Activities||598.98 M||Cash From Investing Activities||-341.33 M||Cash From Operating Activities||-26.25 M||Gross Profit|
|Net Profit||-50.78 M||Operating Profit||-52.22 M||Total Assets||1.63 B||Total Current Assets||1.09 B|
|Total Current Liabilities||80.69 M||Total Debt||Total Liabilities||132.28 M||Total Revenue||18.54 M|
|High 52 week||148.54||Low 52 week||65.07||Last close||73.34||Last change||0.91%|
|RSI||28.58||Average true range||5.13||Beta||1.23||Volume||734.61 K|
|Simple moving average 20 days||-3.14%||Simple moving average 50 days||-10.23%||Simple moving average 200 days||-27.17%|
|Performance Week||5.72%||Performance Month||0.47%||Performance Quart||-24.29%||Performance Half||-26.65%|
|Performance Year||-44.58%||Performance Year-to-date||-42.27%||Volatility daily||4.85%||Volatility weekly||10.84%|
|Volatility monthly||22.22%||Volatility yearly||76.97%||Relative Volume||208.92%||Average Volume||940.78 K|
|New High||New Low|
2019-04-16 19:13:11 | Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
2019-04-16 07:27:00 | Is Alnylam Pharmaceuticals a Buy Now?
2019-04-15 16:49:08 | Alnylam ALNY Reports Phase III ENVISION Data on Givosiran
2019-04-15 07:00:00 | Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
2019-04-12 07:23:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-04-11 09:27:01 | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
2019-04-10 09:20:01 | Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
2019-04-09 10:51:28 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
2019-04-09 09:03:01 | Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
2019-04-08 13:55:03 | Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics
2019-04-08 11:13:56 | Regeneron forays into gene-silencing therapies with Alnylam tie-up
2019-04-08 09:10:55 | Alnylam trades partner Sanofi for Regeneron in $800M deal
2019-03-30 11:31:00 | 2 Biotechs With Big Dates in April
2019-03-26 08:26:49 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-03-18 18:51:10 | Alnylam's ALNY Impressive Pipeline Drives Share Price
2019-03-12 10:32:18 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK
2019-03-09 09:31:02 | Why Is Alnylam ALNY Up 3.1% Since Last Earnings Report?
2019-03-07 16:00:00 | Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
2019-03-07 09:00:02 | Alnylam Stock Down Despite Positive Phase III Givosiran Data
2019-03-06 16:10:08 | Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?
2019-03-06 11:06:00 | Side effects of Alnylam's gene-silencing drug raise concerns, shares slip
2019-03-06 08:20:40 | After trial success, Alnylam plans to seek FDA approval for 2nd drug
2019-03-05 08:06:59 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
2019-03-04 09:19:00 | Can This Biotech Puppy Run With the Big Dogs?
2019-02-28 09:50:02 | Medicines Company MDCO Q4 Loss Widens, Inclisiran in Focus
2019-02-28 07:00:00 | Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
2019-02-25 06:43:34 | FDA panel says Karyopharm's cancer drug shows 'significant toxicity'
2019-02-14 12:01:56 | Is Moderna a Buy?
2019-02-12 10:04:00 | Alnylam Pharmaceuticals Is Launched and Ready for More
2019-02-12 08:10:00 | Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group — What Drives Growth in Today's Competitive Landscape
2019-02-08 14:32:00 | Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT
2019-02-08 08:06:58 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
2019-02-08 07:47:12 | Alnylam's ALNY Q4 Earnings and Revenues Beat Estimates
2019-02-07 23:15:21 | Alnylam Pharmaceuticals, Inc. ALNY Q4 2018 Earnings Conference Call Transcript
2019-02-07 18:15:11 | Alnylam Pharmaceuticals ALNY Reports Q4 Loss, Tops Revenue Estimates
2019-02-07 17:23:14 | Alnylam: 4Q Earnings Snapshot